While a phase II clinical trial (NCT01877083) determined that once-daily oral administration of lenvatinib (24mg) induces relatively low response in RET fusion-positive NSCLC patients (ORR 16%, 4/25 patients), this effect was adequate to improve the median progression-free survival (214). The gene discussed is RET; the disease is non-small cell lung carcinoma.